$CRVO
CervoMed Inc.

2015 Q4 Form 10-Q Financial Statement

#000143774915020645 Filed on November 12, 2015

View on sec.gov

Income Statement

Concept 2015 Q4 2015 Q3 2014 Q3
Revenue $0.00 $0.00 $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $1.290M $420.0K $1.870M
YoY Change -17.31% -77.54% 12.65%
% of Gross Profit
Research & Development $1.270M $922.2K $1.273M
YoY Change -16.99% -27.56%
% of Gross Profit
Depreciation & Amortization $0.00 $5.393K $368.9K
YoY Change -100.0% -98.54% 4832.8%
% of Gross Profit
Operating Expenses $2.570M $13.23M $3.512M
YoY Change -314.17% 276.59% 111.04%
Operating Profit -$1.346M -$3.512M
YoY Change -61.66% 111.04%
Interest Expense -$150.0K $76.17K $86.67K
YoY Change 1400.0% -12.11% 548.48%
% of Operating Profit
Other Income/Expense, Net $1.165K -$83.52K
YoY Change -101.39% -331.49%
Pretax Income -$2.720M -$1.423M -$3.595M
YoY Change -65.48% -60.43% 120.58%
Income Tax $0.00 -$146.0K
% Of Pretax Income
Net Earnings -$2.720M -$1.423M -$3.449M
YoY Change -46.35% -58.76% 126.15%
Net Earnings / Revenue
Basic Earnings Per Share
Diluted Earnings Per Share -$10.46M -$9.467M -$28.75M
COMMON SHARES
Basic Shares Outstanding 18.61M 18.61M 18.67M
Diluted Shares Outstanding 18.61M 18.67M

Balance Sheet

Concept 2015 Q4 2015 Q3 2014 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments $2.000M $14.58M $23.79M
YoY Change -90.86% -38.71% 9050.0%
Cash & Equivalents $1.997M $1.904M $23.79M
Short-Term Investments
Other Short-Term Assets $50.00K $1.050M $2.220M
YoY Change -97.82% -52.7% -23.45%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $2.043M $15.63M $26.01M
YoY Change -91.55% -39.91% 710.24%
LONG-TERM ASSETS
Property, Plant & Equipment $52.00K $63.39K $54.36K
YoY Change -49.18% 16.61% 171.79%
Goodwill $6.900M $985.0K $11.53M
YoY Change -42.77% -91.45%
Intangibles
YoY Change
Long-Term Investments $250.0K
YoY Change
Other Assets $181.5K
YoY Change
Total Long-Term Assets $233.5K $7.748M $24.54M
YoY Change -98.75% -68.42% 98053.74%
TOTAL ASSETS
Total Short-Term Assets $2.043M $15.63M $26.01M
Total Long-Term Assets $233.5K $7.748M $24.54M
Total Assets $2.277M $23.38M $50.55M
YoY Change -94.68% -53.75% 1462.51%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $424.7K $240.4K $105.5K
YoY Change 1.77% 127.8% -93.15%
Accrued Expenses $620.0K $1.790M $1.500M
YoY Change -67.71% 19.33% -62.31%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due $420.0K $250.0K
YoY Change -90.31%
Total Short-Term Liabilities $1.471M $2.035M $2.977M
YoY Change -37.09% -31.65% -68.89%
LONG-TERM LIABILITIES
Long-Term Debt $820.0K $0.00 $0.00
YoY Change
Other Long-Term Liabilities $28.27K
YoY Change
Total Long-Term Liabilities $28.27K $0.00 $0.00
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities $1.471M $2.035M $2.977M
Total Long-Term Liabilities $28.27K $0.00 $0.00
Total Liabilities $2.318M $4.309M $7.748M
YoY Change -49.75% -44.38% -19.04%
SHAREHOLDERS EQUITY
Retained Earnings -$42.15M -$96.00M -$70.22M
YoY Change -44.01% 36.71%
Common Stock $42.11M $115.1M $113.0M
YoY Change -62.88% 1.81%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity -$41.62K $19.07M $42.80M
YoY Change
Total Liabilities & Shareholders Equity $2.277M $23.38M $50.55M
YoY Change -94.68% -53.75% 1464.93%

Cashflow Statement

Concept 2015 Q4 2015 Q3 2014 Q3
OPERATING ACTIVITIES
Net Income -$2.720M -$1.423M -$3.449M
YoY Change -46.35% -58.76% 126.15%
Depreciation, Depletion And Amortization $0.00 $5.393K $368.9K
YoY Change -100.0% -98.54% 4832.8%
Cash From Operating Activities -$2.270M -$980.0K -$1.980M
YoY Change 17.62% -50.51% 500.0%
INVESTING ACTIVITIES
Capital Expenditures -$30.00K $0.00 $0.00
YoY Change -40.0%
Acquisitions
YoY Change
Other Investing Activities $0.00 $0.00 $0.00
YoY Change
Cash From Investing Activities -$30.00K $0.00 $0.00
YoY Change -40.0%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 2.390M 0.000 -1.380M
YoY Change 2887.5% -100.0% -370.59%
NET CHANGE
Cash From Operating Activities -2.270M -980.0K -1.980M
Cash From Investing Activities -30.00K 0.000 0.000
Cash From Financing Activities 2.390M 0.000 -1.380M
Net Change In Cash 90.00K -980.0K -3.360M
YoY Change -104.74% -70.83% -1966.67%
FREE CASH FLOW
Cash From Operating Activities -$2.270M -$980.0K -$1.980M
Capital Expenditures -$30.00K $0.00 $0.00
Free Cash Flow -$2.240M -$980.0K -$1.980M
YoY Change 19.15% -50.51%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
dei Entity Well Known Seasoned Issuer
EntityWellKnownSeasonedIssuer
No
dei Amendment Flag
AmendmentFlag
false
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2015
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q3
CY2015Q3 resx Accrued Board Fees
AccruedBoardFees
55938
CY2014Q4 resx Accrued Board Fees
AccruedBoardFees
55000
CY2015Q3 resx Additional Allocated Sharebased Compensation Expense
AdditionalAllocatedSharebasedCompensationExpense
45953
resx Additional Allocated Sharebased Compensation Expense
AdditionalAllocatedSharebasedCompensationExpense
45953
resx Class Of Warrant Or Right Weighted Average Exercise Price
ClassOfWarrantOrRightWeightedAverageExercisePrice
8.22
CY2015Q3 resx Contractual Obligation Due In Next Rolling Twelve Months
ContractualObligationDueInNextRollingTwelveMonths
72561
CY2015Q3 resx Contractual Obligation Due In Next Rolling Year Three
ContractualObligationDueInNextRollingYearThree
31081
CY2015Q3 resx Contractual Obligation Due In Next Rolling Year Two
ContractualObligationDueInNextRollingYearTwo
73996
dei Entity Filer Category
EntityFilerCategory
Smaller Reporting Company
dei Entity Voluntary Filers
EntityVoluntaryFilers
No
dei Trading Symbol
TradingSymbol
resx
CY2015Q4 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
18614968
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Document Period End Date
DocumentPeriodEndDate
2015-09-30
dei Document Type
DocumentType
10-Q
resx Gain Loss On Settlement Of Notes Payable
GainLossOnSettlementOfNotesPayable
-876543
resx Gain Loss On Settlement Of Notes Payable
GainLossOnSettlementOfNotesPayable
CY2015Q3 resx Gain Loss On Settlement Of Notes Payable
GainLossOnSettlementOfNotesPayable
resx Conversion Of Accounts Payable To Notes Payable
ConversionOfAccountsPayableToNotesPayable
resx Conversion Of Accounts Payable To Notes Payable
ConversionOfAccountsPayableToNotesPayable
407998
resx Depreciation Depletion And Amortization Including Discontinued Operations
DepreciationDepletionAndAmortizationIncludingDiscontinuedOperations
17875
resx Depreciation Depletion And Amortization Including Discontinued Operations
DepreciationDepletionAndAmortizationIncludingDiscontinuedOperations
883995
resx Fair Value Of Stock And Stock Warrants Issued As Payment Of Accounts Payable And Accrued Liabilites
FairValueOfStockAndStockWarrantsIssuedAsPaymentOfAccountsPayableAndAccruedLiabilites
resx Fair Value Of Stock And Stock Warrants Issued As Payment Of Accounts Payable And Accrued Liabilites
FairValueOfStockAndStockWarrantsIssuedAsPaymentOfAccountsPayableAndAccruedLiabilites
1361404
resx Fair Value Of Stock And Stock Warrants Issued To Related Party As Payment Of Note Payable
FairValueOfStockAndStockWarrantsIssuedToRelatedPartyAsPaymentOfNotePayable
resx Fair Value Of Stock And Stock Warrants Issued To Related Party As Payment Of Note Payable
FairValueOfStockAndStockWarrantsIssuedToRelatedPartyAsPaymentOfNotePayable
1105475
resx Fair Value Of Stock Issued As Payment Of Note Payable
FairValueOfStockIssuedAsPaymentOfNotePayable
resx Fair Value Of Stock Issued As Payment Of Note Payable
FairValueOfStockIssuedAsPaymentOfNotePayable
517945
CY2014Q3 resx Gain Loss On Settlement Of Notes Payable
GainLossOnSettlementOfNotesPayable
resx Gains Losses On Extinguishment Of Related Party Debt
GainsLossesOnExtinguishmentOfRelatedPartyDebt
-1829562
resx Gains Losses On Extinguishment Of Related Party Debt
GainsLossesOnExtinguishmentOfRelatedPartyDebt
CY2015Q3 resx Gains Losses On Extinguishment Of Related Party Debt
GainsLossesOnExtinguishmentOfRelatedPartyDebt
CY2014Q3 resx Gains Losses On Extinguishment Of Related Party Debt
GainsLossesOnExtinguishmentOfRelatedPartyDebt
CY2014Q4 resx Market Capitalization
MarketCapitalization
66100000
CY2015Q3 resx Market Capitalization
MarketCapitalization
16700000
resx Non Cash Stock Warrant Expense
NonCashStockWarrantExpense
499003
resx Non Cash Stock Warrant Expense
NonCashStockWarrantExpense
resx Noncash Or Part Noncash Acquisition Noncash Financial Or Equity Instrument Consideration
NoncashOrPartNoncashAcquisitionNoncashFinancialOrEquityInstrumentConsideration
resx Noncash Or Part Noncash Acquisition Noncash Financial Or Equity Instrument Consideration
NoncashOrPartNoncashAcquisitionNoncashFinancialOrEquityInstrumentConsideration
6800000
CY2015Q3 resx Number Of Phase I Clinicial Trials Completed
NumberOfPhaseIClinicialTrialsCompleted
2
CY2015Q3 resx Prepaid Expenses Deposits And Other Assets
PrepaidExpensesDepositsAndOtherAssets
1049254
CY2014Q4 resx Prepaid Expenses Deposits And Other Assets
PrepaidExpensesDepositsAndOtherAssets
2286930
CY2014Q3 resx Prior Period Reclassification Adjustment Amortization Of Prepaid Expense Asset
PriorPeriodReclassificationAdjustmentAmortizationOfPrepaidExpenseAsset
286774
resx Prior Period Reclassification Adjustment Amortization Of Prepaid Expense Asset
PriorPeriodReclassificationAdjustmentAmortizationOfPrepaidExpenseAsset
860322
resx Prior Period Reclassification Adjustment Employee And Director Stockbased Compensation Noncash
PriorPeriodReclassificationAdjustmentEmployeeAndDirectorStockbasedCompensationNoncash
1075131
CY2014Q3 resx Prior Period Reclassification Adjustment Income Tax Benefit
PriorPeriodReclassificationAdjustmentIncomeTaxBenefit
145999
resx Prior Period Reclassification Adjustment Income Tax Benefit
PriorPeriodReclassificationAdjustmentIncomeTaxBenefit
384128
CY2014Q3 resx Prior Period Reclassification Adjustment Legal And Professional Services
PriorPeriodReclassificationAdjustmentLegalAndProfessionalServices
294390
resx Prior Period Reclassification Adjustment Legal And Professional Services
PriorPeriodReclassificationAdjustmentLegalAndProfessionalServices
810680
resx Prior Period Reclassification Adjustment Loss On Settlement Of Issuing Shares For Liabilities
PriorPeriodReclassificationAdjustmentLossOnSettlementOfIssuingSharesForLiabilities
408953
resx Prior Period Reclassification Adjustment Notes Payable Settlements
PriorPeriodReclassificationAdjustmentNotesPayableSettlements
73420
CY2014Q3 resx Prior Period Reclassification Adjustment Stockbased Compensation And Warrant Expense
PriorPeriodReclassificationAdjustmentStockbasedCompensationAndWarrantExpense
783932
resx Prior Period Reclassification Adjustment Stockbased Compensation And Warrant Expense
PriorPeriodReclassificationAdjustmentStockbasedCompensationAndWarrantExpense
1075131
CY2015Q3 resx Rent Liability For Facilities No Longer Occupied
RentLiabilityForFacilitiesNoLongerOccupied
424155
CY2014Q4 resx Rent Liability For Facilities No Longer Occupied
RentLiabilityForFacilitiesNoLongerOccupied
808418
CY2015Q3 us-gaap Accounts Payable Current
AccountsPayableCurrent
240381
CY2014Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
417307
CY2015Q3 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
108580
CY2014Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
217663
CY2015Q3 us-gaap Accrued Salaries Current
AccruedSalariesCurrent
579009
CY2014Q4 us-gaap Accrued Salaries Current
AccruedSalariesCurrent
741032
CY2015Q3 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
15750
CY2014Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
6719
CY2015Q3 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
115050722
CY2014Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
113437384
CY2015Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
481237
CY2014Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
783932
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
1613854
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
1075131
CY2014Q3 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
367019
us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
875024
CY2015Q3 us-gaap Assets
Assets
23377867
CY2014Q4 us-gaap Assets
Assets
42778751
CY2015Q3 us-gaap Assets Current
AssetsCurrent
15629850
CY2014Q4 us-gaap Assets Current
AssetsCurrent
24170817
CY2015Q3 us-gaap Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Deferred Tax Liabilities Noncurrent
BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilitiesNoncurrent
2274526
CY2014Q4 us-gaap Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Deferred Tax Liabilities Noncurrent
BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilitiesNoncurrent
2274526
CY2014Q1 us-gaap Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Intangible Assets Other Than Goodwill
BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill
6449628
CY2014Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
21883887
CY2013Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
254964
CY2015Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
14580596
CY2014Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
23788336
us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
-7303291
CY2015Q3 us-gaap Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights
ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
4788066
us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
23533372
CY2015Q3 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2014Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2015Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2014Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2015Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
1000000000
CY2014Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
1000000000
CY2015Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
18614968
CY2014Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
18614968
CY2015Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
18614968
CY2014Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
18614968
CY2015Q3 us-gaap Common Stock Value
CommonStockValue
18615
CY2014Q4 us-gaap Common Stock Value
CommonStockValue
18615
CY2015Q3 us-gaap Contractual Obligation
ContractualObligation
177638
CY2015Q3 us-gaap Cost Method Investments
CostMethodInvestments
250000
CY2014Q4 us-gaap Cost Method Investments
CostMethodInvestments
us-gaap Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
us-gaap Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
-384128
CY2015Q3 us-gaap Depreciation
Depreciation
5393
us-gaap Depreciation
Depreciation
17875
CY2014Q3 us-gaap Depreciation
Depreciation
1905
us-gaap Depreciation
Depreciation
8971
CY2015Q3 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
5393
CY2014Q3 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
368924
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
17875
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
883995
CY2015Q3 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.71
CY2014Q3 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.18
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-1.11
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.76
us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
P1Y240D
CY2015Q3 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
3156902
CY2015Q3 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
6449628
CY2014Q4 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
6449628
us-gaap Gain Loss On Disposition Of Assets
GainLossOnDispositionOfAssets
-49278
us-gaap Gain Loss On Disposition Of Assets
GainLossOnDispositionOfAssets
-6056
CY2015Q3 us-gaap Gain Loss On Disposition Of Assets
GainLossOnDispositionOfAssets
-49278
CY2014Q3 us-gaap Gain Loss On Disposition Of Assets
GainLossOnDispositionOfAssets
-6056
us-gaap Gain Loss On Disposition Of Assets1
GainLossOnDispositionOfAssets1
-49278
us-gaap Gain Loss On Disposition Of Assets1
GainLossOnDispositionOfAssets1
-6056
CY2015Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
1456567
CY2014Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
1869840
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
5298945
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
4091530
CY2015Q3 us-gaap Goodwill
Goodwill
985000
CY2014Q4 us-gaap Goodwill
Goodwill
12055991
CY2014 us-gaap Goodwill Impairment Loss
GoodwillImpairmentLoss
0
CY2015Q3 us-gaap Goodwill Impairment Loss
GoodwillImpairmentLoss
11070991
us-gaap Goodwill Impairment Loss
GoodwillImpairmentLoss
11070991
us-gaap Goodwill Impairment Loss
GoodwillImpairmentLoss
CY2014Q3 us-gaap Goodwill Impairment Loss
GoodwillImpairmentLoss
CY2015Q3 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-13224495
CY2014Q3 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-3595469
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-20710233
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-9669005
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
CY2015Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
CY2014Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-145999
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-384128
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
-303989
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
-2642272
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-738157
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-540069
CY2015Q3 us-gaap Interest Expense
InterestExpense
CY2014Q3 us-gaap Interest Expense
InterestExpense
86670
us-gaap Interest Expense
InterestExpense
us-gaap Interest Expense
InterestExpense
281548
CY2015Q3 us-gaap Liabilities
Liabilities
4309137
CY2014Q4 us-gaap Liabilities
Liabilities
4613126
CY2015Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
23377867
CY2014Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
42778751
CY2015Q3 us-gaap Liabilities Current
LiabilitiesCurrent
2034611
CY2014Q4 us-gaap Liabilities Current
LiabilitiesCurrent
2338600
us-gaap Long Term Purchase Commitment Amount
LongTermPurchaseCommitmentAmount
528009
us-gaap Nature Of Operations
NatureOfOperations
<div style="display: inline; font-family: times new roman; font-size: 10pt"><table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 100%; TEXT-INDENT: 0px; width: 700px;" cellspacing="0" cellpadding="0" border="0"> <tr> <td style="WIDTH: 36pt; VERTICAL-ALIGN: top"><div style=" MARGIN-BOTTOM: 0pt; TEXT-ALIGN: left; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><div style="display: inline; font-weight: bold;">1.</div></div></div></td> <td style="VERTICAL-ALIGN: top"> <div style=" MARGIN-BOTTOM: 0pt; TEXT-ALIGN: left; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><div style="display: inline; font-weight: bold;">Description of Business</div></div></div></td> </tr> </table> <div style=" MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</div></div> <div style=" TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25; TEXT-INDENT: 36pt"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">RestorGenex Corporation (&#x201c;Company&#x201d;) is a specialty biopharmaceutical company focused on developing products for oncology, ophthalmology and dermatology. The Company&#x2019;s lead product is a novel PI3K/Akt/mTOR pathway inhibitor which has completed two Phase I clinical trials for age-related macular degeneration and is in pre-clinical development in oncology, specifically glioblastoma multiforme. The Company&#x2019;s current pipeline also includes a &#x201c;soft&#x201d; anti-androgen compound for the treatment of acne vulgaris. The Company&#x2019;s novel inhibition of the PI3K/Akt/mTOR pathway and unique targeting of the androgen receptor show promise in a number of additional diseases, which the Company is evaluating for the purpose of creating innovative therapies that are safe and effective treatments to satisfy unmet medical needs. In addition, as a part of the Company&#x2019;s corporate strategy, it continues to seek, consider, and if appropriate, implement strategic alternatives with respect to its products and the Company, including licenses, business collaborations and other business combinations or transactions with other pharmaceutical and biotechnology companies.</div></div></div>
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
30633293
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-278227
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-7025064
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-7099921
CY2015Q3 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-13224495
CY2014Q3 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-3449470
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-20710233
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-9284877
CY2015Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
1165
CY2014Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-83519
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
5318
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-2984056
CY2015Q3 us-gaap Operating Expenses
OperatingExpenses
13225660
CY2014Q3 us-gaap Operating Expenses
OperatingExpenses
3511950
us-gaap Operating Expenses
OperatingExpenses
20715551
us-gaap Operating Expenses
OperatingExpenses
6684949
CY2015Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-13225660
CY2014Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-3511950
us-gaap Operating Income Loss
OperatingIncomeLoss
-20715551
us-gaap Operating Income Loss
OperatingIncomeLoss
-6684949
CY2015Q3 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
1794230
CY2014Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
1921293
CY2015Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
1165
CY2014Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
3151
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
5318
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
3597
CY2015Q3 us-gaap Other Sundry Liabilities Current
OtherSundryLiabilitiesCurrent
173044
CY2014Q4 us-gaap Other Sundry Liabilities Current
OtherSundryLiabilitiesCurrent
99180
us-gaap Payments To Acquire Investments
PaymentsToAcquireInvestments
250000
us-gaap Payments To Acquire Investments
PaymentsToAcquireInvestments
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
28227
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
CY2014Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
1273186
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
3360057
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
1709424
CY2015Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-96000607
CY2014Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-75290374
us-gaap Prior Period Reclassification Adjustment Description
PriorPeriodReclassificationAdjustmentDescription
<div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style=" TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><div style="display: inline; font-style: italic;">Correction of Prior Period Misstatements</div></div></div><div style=" MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</div></div><div style=" TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25; TEXT-INDENT: 36pt"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">In the fourth quarter of 2014, the Company recorded certain adjustments for misstatements related to prior 2014 interim and prior annual periods that had been deemed immaterial.&nbsp; See Note 2 to the Company&#x2019;s consolidated financial statements for the year ended December 31, 2014, included in the Company&#x2019;s annual report on Form 10-K for the year ended December 31, 2014, for further information as to the nature of the adjustments recorded in the fourth quarter of 2014.</div></div><div style=" MARGIN-BOTTOM: 0px; MARGIN-TOP: 0px"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"></div>&nbsp;</div><div style=" TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25; TEXT-INDENT: 36pt"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">For the nine months ended September 30, 2014 consolidated statements of operations, the current period presentation of $1,829,562 of &#x201c;loss on settlement of notes payable &#x2013; related parties&#x201d; and $876,543 of &#x201c;loss on settlement of notes payable&#x201d; were moved to other expenses from operating expenses reflecting the correction of an immaterial prior period misstatement related to the classification of losses on settlement of notes payable.</div></div><div style=" MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</div></div><div style=" TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25; TEXT-INDENT: 36pt"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">$145,999 and $384,128 of income tax benefit recognized in the three and nine months ended September 30, 2014 was reclassified to benefit from income taxes in the current period condensed consolidated statements of operations from other (income) expense in the prior year presentation, representing the correction of a prior period immaterial misstatement related to the presentation of income tax benefit.</div></div><div style=" MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</div></div><div style=" TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><div style="display: inline; font-style: italic;">Reclassifications</div></div></div><div style=" MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</div></div><div style=" TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25; TEXT-INDENT: 36pt"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Certain 2014 amounts were reclassified to conform to the manner of presentation in the current period. These reclassifications included:</div></div><div style=" MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</div></div><div style=" TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25; TEXT-INDENT: 36pt"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">$286,774 and $860,322 of amortization expense recognized in the three and nine months ended September 30, 2014 condensed consolidated statements of operations from amortizing the prepaid expense asset for general financial advisory and investment banking services described in Note 4 to these condensed consolidated financial statements was reclassified to &#x201c;general and administrative&#x201d; expense in the current period condensed consolidated statements of operations presentation from &#x201c;depreciation and amortization&#x201d; expense where it was presented in the prior period. In the condensed consolidated statements of cash flows, the same amount was reclassified within the &#x201c;cash flows used in operating activities&#x201d; section from &#x201c;depreciation and amortization&#x201d; in the prior period presentation to &#x201c;prepaid expenses, deposits and other assets&#x201d; in the current period presentation.</div></div><div style=" MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</div></div><div style=" TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25; TEXT-INDENT: 36pt"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">$783,932 and $1,075,131 of expense recognized in the three and nine months ended September 30, 2014 condensed consolidated statements of operations presentation from stock-based compensation and warrant expense described in Notes 9 and 10 to these condensed consolidated financial statements was reclassified to &#x201c;general and administrative&#x201d; ($440,935 and $699,310 for the three and nine months ended September 30, 2014) and &#x201c;research and development&#x201d; ($342,997 and $375,821 for the three and nine months ended September 30, 2014) in the current period condensed consolidated statements of operations presentation from &#x201c;warrants, options and stock compensation&#x201d; expense in the prior period presentation.&nbsp; In the condensed consolidated statements of cash flows, the same amount was reclassified within the &#x201c;cash flows used in operating activities&#x201d; section from &#x201c;warrants, options and stock compensation&#x201d; in the prior period presentation to &#x201c;employee and director stock-based compensation &#x2013; non-cash&#x201d; in the amount of $1,075,131 in the current period presentation.</div></div><div style=" MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</div></div><div style=" TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25; TEXT-INDENT: 36pt"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">$294,390 and $810,680 of legal and professional services expense recognized in the three and nine months ended September 30, 2014 condensed consolidated statements of operations was reclassified to &#x201c;general and administrative&#x201d; expense in the current period condensed consolidated statements of operations presentation from &#x201c;legal and professional services&#x201d; expense in the prior period presentation. </div></div><div style=" MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</div></div><div style=" TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25; TEXT-INDENT: 36pt"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">$408,953 of &#x201c;loss on settlement of accounts payable and accrued liabilities&#x201d; recognized in the nine months ended September 30, 2014 condensed consolidated statements of operations was reclassified to &#x201c;general and administrative&#x201d; expense in the current period condensed consolidated statements of operations presentation from &#x201c;loss on settlement of accounts payable and accrued liabilities&#x201d; in the prior period presentation.</div></div><div style=" MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</div></div><div style=" TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25; TEXT-INDENT: 36pt"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">In the condensed consolidated statements of cash flows within net cash (used in) operating activities, $408,953 from loss on settlement of issuing shares for liabilities and $73,420 from noncash interest expense on notes payable in the prior period presentation was reclassified to accounts payable and accrued liabilities in the amount of $482,373 in the current period presentation.</div></div></div></div>
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
31773293
us-gaap Proceeds From Notes Payable
ProceedsFromNotesPayable
us-gaap Proceeds From Notes Payable
ProceedsFromNotesPayable
400000
CY2015Q3 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
79139
CY2014Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
109034
CY2015Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
63389
CY2014Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
102315
us-gaap Repayments Of Notes Payable
RepaymentsOfNotesPayable
us-gaap Repayments Of Notes Payable
RepaymentsOfNotesPayable
1540000
CY2015Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
692709
CY2015Q3 us-gaap Severance Costs1
SeveranceCosts1
CY2014Q3 us-gaap Severance Costs1
SeveranceCosts1
us-gaap Severance Costs1
SeveranceCosts1
967683
us-gaap Severance Costs1
SeveranceCosts1
us-gaap Share Based Compensation
ShareBasedCompensation
1613854
us-gaap Share Based Compensation
ShareBasedCompensation
1075131
CY2015Q2 us-gaap Share Price
SharePrice
2.80
CY2015Q3 us-gaap Share Price
SharePrice
0.90
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Expiration Period
SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod
P90D
CY2015Q2 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Expiration Period
SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod
P1Y
us-gaap Stock Issued During Period Shares New Issues
StockIssuedDuringPeriodSharesNewIssues
0
CY2015Q3 us-gaap Stock Issued During Period Shares New Issues
StockIssuedDuringPeriodSharesNewIssues
0
us-gaap Stock Repurchased And Retired During Period Shares
StockRepurchasedAndRetiredDuringPeriodShares
0
CY2015Q3 us-gaap Stock Repurchased And Retired During Period Shares
StockRepurchasedAndRetiredDuringPeriodShares
0
CY2014Q4 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
38165625
CY2015Q3 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
19068730
CY2015Q3 us-gaap Supplemental Unemployment Benefits Severance Benefits
SupplementalUnemploymentBenefitsSeveranceBenefits
453504
CY2014Q4 us-gaap Supplemental Unemployment Benefits Severance Benefits
SupplementalUnemploymentBenefitsSeveranceBenefits
0
CY2014Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
18671121
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
18614968
us-gaap Use Of Estimates
UseOfEstimates
<div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style=" TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><div style="display: inline; font-style: italic;">Use of Estimates</div></div></div><div style=" MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</div></div><div style=" TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25; TEXT-INDENT: 36pt"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">The preparation of the Company&#x2019;s condensed consolidated financial statements in accordance with U.S.&nbsp;GAAP requires the Company to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenues and expenses and the disclosure of contingent assets and liabilities in the Company&#x2019;s condensed consolidated financial statements and accompanying notes. Although these estimates are based on the Company&#x2019;s knowledge of current events and actions that the Company may undertake in the future, actual results may differ from such estimates and assumptions.</div></div></div></div>
CY2015Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
18614968
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
12155041
CY2015Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
18614968
CY2014Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
18671121
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
18614968
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
12155041

Files In Submission

Name View Source Status
0001437749-15-020645-index-headers.html Edgar Link pending
0001437749-15-020645-index.html Edgar Link pending
0001437749-15-020645.txt Edgar Link pending
0001437749-15-020645-xbrl.zip Edgar Link pending
a1.jpg Edgar Link pending
ex31-1.htm Edgar Link pending
ex31-2.htm Edgar Link pending
ex32-1.htm Edgar Link pending
ex32-2.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
resx-20150930.xml Edgar Link completed
resx-20150930.xsd Edgar Link pending
resx-20150930_cal.xml Edgar Link unprocessable
resx-20150930_def.xml Edgar Link unprocessable
resx-20150930_lab.xml Edgar Link unprocessable
resx-20150930_pre.xml Edgar Link unprocessable
resx20150930_10q.htm Edgar Link pending
Show.js Edgar Link pending